Strain variation and antigenic divergence among Bordetella pertussis circulating strains isolated from patients in Iran
暂无分享,去创建一个
F. Shahcheraghi | S. Zahraei | V. Nikbin | Fatemah Sadeghpour Heravi | Pouran Badiri | Nazanin Jannesar Ahmadi | Masomeh Nakhost Lotfi
[1] K. Auranen,et al. Surveillance of Circulating Bordetella pertussis Strains in Europe during 1998 to 2015 , 2018, Journal of Clinical Microbiology.
[2] Ross M. Graham,et al. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance , 2018, Medical Microbiology and Immunology.
[3] F. Shahcheraghi,et al. Molecular detection of Bordetella holmesii in two infants with pertussis-like syndrome: the first report from Iran , 2017, Iranian journal of microbiology.
[4] M. Decker,et al. Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccine , 2016, Human vaccines & immunotherapeutics.
[5] V. Sintchenko,et al. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model. , 2015, Vaccine.
[6] N. Guiso,et al. New Data on Vaccine Antigen Deficient Bordetella pertussis Isolates , 2015, Vaccines.
[7] F. Mooi,et al. The pertussis problem: classical epidemiology and strain characterization should go hand in hand. , 2015, Jornal de pediatria.
[8] F. Shahcheraghi,et al. Virulence Factors Variation Among Bordetella Pertussis Isolates in Iran , 2015, International journal of molecular and cellular medicine.
[9] F. Shahcheraghi,et al. Allelic variations between vaccine strains and circulating strains in pxtP of Bordetella pertussis in Iran , 2015 .
[10] Carol Glaser,et al. Pertussis Epidemic — California, 2014 , 2014, MMWR. Morbidity and mortality weekly report.
[11] Daniel R Hogan,et al. Neonatal cause-of-death estimates for the early and late neonatal periods for 194 countries: 2000–2013 , 2014, Bulletin of the World Health Organization.
[12] N. Guiso,et al. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines , 2014, Expert review of vaccines.
[13] P. Bryan,et al. Safety of pertussis vaccination in pregnant women in UK: observational study , 2014, BMJ : British Medical Journal.
[14] H. Zeraati,et al. Genetic Profile Variation in Vaccine Strains and Clinical Isolates of Bordetella pertussis Recovered from Iranian Patients , 2014, Avicenna journal of medical biotechnology.
[15] V. Sintchenko,et al. Rapid Increase in Pertactin-deficient Bordetella pertussis Isolates, Australia , 2014, Emerging infectious diseases.
[16] G. Fedele,et al. The Virulence Factors of Bordetella pertussis: Talented Modulators of Host Immune Response , 2013, Archivum Immunologiae et Therapiae Experimentalis.
[17] A. V. D. van der Ark,et al. Genome-Wide Gene Expression Analysis of Bordetella pertussis Isolates Associated with a Resurgence in Pertussis: Elucidation of Factors Involved in the Increased Fitness of Epidemic Strains , 2013, PloS one.
[18] J. Zipprich,et al. California pertussis epidemic, 2010. , 2012, The Journal of pediatrics.
[19] F. Mooi,et al. Pulsed-Field Gel Electrophoresis Analysis of Bordetella pertussis Isolates Circulating in Europe from 1998 to 2009 , 2012, Journal of Clinical Microbiology.
[20] J. Mertsola,et al. Appearance of Bordetella pertussis Strains Not Expressing the Vaccine Antigen Pertactin in Finland , 2012, Clinical and Vaccine Immunology.
[21] K. Mills,et al. Immunity to the respiratory pathogen Bordetella pertussis , 2012, Mucosal Immunology.
[22] T. Kallonen. Evolution of Bordetella pertussis post vaccination , 2011 .
[23] F. Mooi,et al. Pertussis: a matter of immune modulation. , 2011, FEMS microbiology reviews.
[24] F. Mooi,et al. Studies on Prn Variation in the Mouse Model and Comparison with Epidemiological Data , 2011, PloS one.
[25] F. Mooi,et al. Comparative genomics of prevaccination and modern Bordetella pertussis strains , 2010, BMC Genomics.
[26] A. Abe,et al. Synergic Effect of Genotype Changes in Pertussis Toxin and Pertactin on Adaptation to an Acellular Pertussis Vaccine in the Murine Intranasal Challenge Model , 2010, Clinical and Vaccine Immunology.
[27] B. Kříž,et al. A steady rise in incidence of pertussis since nineties in the Czech Republic. , 2010, Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne.
[28] F. Mooi,et al. An investigation into the cause of the 1983 whooping cough epidemic in the Netherlands. , 2009, Vaccine.
[29] B. Ewald,et al. The epidemiology of pertussis in the Australian Capital Territory, 1999 to 2005--epidemics of testing, disease or false positives? , 2007, Communicable diseases intelligence quarterly report.
[30] F. Mooi,et al. Bordetella pertussis Strains Circulating in Europe in 1999 to 2004 as Determined by Pulsed-Field Gel Electrophoresis , 2007, Journal of Clinical Microbiology.
[31] Deborah A. Adams,et al. Summary of notifiable diseases --- United States, 2005. , 2007, MMWR. Morbidity and mortality weekly report.
[32] F. Mooi,et al. Adaptive evolution of the Bordetella autotransporter pertactin , 2006, Journal of evolutionary biology.
[33] C. Locht,et al. Temporal analysis of French Bordetella pertussis isolates by comparative whole-genome hybridization. , 2006, Microbes and infection.
[34] M. Steinbakk,et al. [Whooping cough--an increasing problem in Norway]. , 2006, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[35] O. Bjørnstad,et al. Evolution and emergence of Bordetella in humans. , 2005, Trends in microbiology.
[36] F. Mooi,et al. Analysis of Bordetella pertussis Populations in European Countries with Different Vaccination Policies , 2005, Journal of Clinical Microbiology.
[37] H. Hallander,et al. Reference System for Characterization of Bordetella pertussis Pulsed-Field Gel Electrophoresis Profiles , 2004, Journal of Clinical Microbiology.
[38] R. George,et al. Genotypic Variation in the Bordetella pertussis Virulence Factors Pertactin and Pertussis Toxin in Historical and Recent Clinical Isolates in the United Kingdom , 2001, Infection and Immunity.
[39] W. Wattigney,et al. Molecular epidemiology of Bordetella pertussis by pulsed-field gel electrophoresis profile: Cincinnati, 1989-1996. , 2001, The Journal of infectious diseases.
[40] T. Popović,et al. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. , 2000, The Journal of infectious diseases.
[41] F. Mooi,et al. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. , 2000, Emerging infectious diseases.
[42] N. Guiso. Bordetella pertussis: why is it still circulating? , 2014, The Journal of infection.
[43] M. V. Gent,et al. Molecular studies into the causes of the resurgence of Bordetella pertussis in the face of vaccination , 2013 .
[44] F. Mooi. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. , 2010, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[45] D. Rabczenko,et al. [Increase in the incidence of pertussis and quality of whole-cell pertussis component of the DTP vaccine produced in Poland. Part I. Potency of DTP vaccine]. , 2004, Przeglad epidemiologiczny.
[46] F. Mooi,et al. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? , 2001, Emerging infectious diseases.
[47] E. Hewlett,et al. Virulence factors of Bordetella pertussis. , 1986, Annual review of microbiology.